Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chugai Pharmaceutical : announced Organizational Changes

10/25/2021 | 07:27am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the following organizational changes, effective January 1, 2022.

1. Establishment of Digital Transformation Unit

Digital Transformation Unit will be newly established to reorganize the digital and IT functions. Digital and IT Supervisory Div. will be abolished accordingly.

Digital Strategy Dept. and IT Solutions Dept., both currently exist under Digital and IT Supervisory Div., will be transferred to Digital Transformation Unit.

Overview

By reorganizing the digital and IT functions as a unit, Digital Transformation Unit will further promote company-wide digital and IT strategies. By deeply involved in individual IT and Digital projects, the Unit will accumulate and deploy knowledge, enhance governance and contain costs so that the company may accelerate the realization of digital transformation (DX), one of the key drivers in TOP I 2030.

2. Reorganization of Drug Safety Div. and Quality and Regulatory Compliance Unit

Safety Strategy Dept. will be renamed Safety Science Dept., and Pharmacovigilance Dept. will be renamed Drug Safety Data Management Dept. This is to strengthen the safety science and data management functions by clarifying the roles of each function.

The data science functions spread across each department will be reorganized as follows:

Planning and analysis relating to safety strategy: Safety Science Dept.

Surveillance management and solution provision: Risk Communication Dept.

Basic business operations of each department and functions related to DX will be consolidated in Drug Safety Coordination Dept. To achieve both quality and efficiency in quality management, reorganization with Quality & Regulatory Compliance Unit will be carried out.

Real World Data Science Dept. will be abolished, and its pharmacovigilance function will be transferred to other departments.

With RED SHIFT in mind, reorganization will take place to strengthen the safety science function and thereby ensure consistent and appropriate risk assessment and risk management of Chugai products from the early development stage to the post-marketing phase. The reorganization also aims to strategically and quickly utilize the data science function as it relates to real-world data including post-marketing surveillance.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. -4.03% 3528 End-of-day quote.-35.89%
ROCHE HOLDING AG 1.46% 367.55 Delayed Quote.18.95%
All news about CHUGAI PHARMACEUTICAL CO., LTD.
04:27aChugai - Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai..
AQ
12/03CHUGAI PHARMACEUTICAL : Towa Pharmaceutical Receives Approval for Authorized Generic Versi..
PU
12/02Chugai Launches a New Educational Website 'So-Zo LABO' Aiming for a Society that Embrac..
AQ
12/01CHUGAI PHARMACEUTICAL : Launches a New Educational Website “So-Zo LABO” Aiming..
PU
11/26Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
11/25CHUGAI PHARMACEUTICAL : Anti-Cancer Agent Herceptin Approved for Additional Indication of ..
PU
11/23Beijing IP Court To Hear China's First Case Of Patent Linkage
AQ
11/18CHUGAI PHARMACEUTICAL : Personnel Changes
PU
11/18CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
11/16CHUGAI PHARMACEUTICAL : Atea Announces Update on Collaboration with Roche for AT-527
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 975 B 8 589 M 8 589 M
Net income 2021 292 B 2 575 M 2 575 M
Net cash 2021 461 B 4 061 M 4 061 M
P/E ratio 2021 19,9x
Yield 2021 1,93%
Capitalization 5 801 B 51 127 M 51 118 M
EV / Sales 2021 5,48x
EV / Sales 2022 5,18x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 3 528,00 JPY
Average target price 4 785,38 JPY
Spread / Average Target 35,6%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-35.89%53 454
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641